Andrew Callos

EVP Andrew Callos sells 15,000 shares ($1.1M) at $74.08 via scheduled 10b5-1 plan; retains 58,555 shares plus 39,000 option rights.

Andrew Callos, EVP and Chief Commercial Officer, sold 15,000 shares for $1,111,200.00 on 2026-06-01 at $74.08 per share as part of a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings to 58,555 shares while retaining 39,000 non-qualified stock option rights. Stock price at transaction was $74.08; current price is $73.68, with the stock trading -8.1% from its 52-week high of $80.20 but +16.3% over the prior 30 days and +21.3% over the prior 90 days. Callos's prior five sales at CYTK show mixed timing outcomes: three consecutive sells in early 2026 were followed by +18.1%, +7.9%, and +7.8% respective 30-day returns, while a December 2025 sale preceded a -6.4% 30-day decline and a March 2025 sale preceded a -11.4% 30-day decline. The company posted $19,355,000.00 in latest-quarter revenue but remains unprofitable with $-206,031,000.00 net income for the most recent full fiscal year, though annual revenue growth reached +376.6% year-over-year. As a scheduled trade under a 10b5-1 plan, this sale reflects administrative scheduling rather than discretionary market timing decisions.

Chief Commercial Officer exercises and immediately sells 15,857 shares at profit; pure stock-compensation monetization with no net position change.

Andrew Callos, EVP and Chief Commercial Officer, exercised and sold 15,857 shares on the same day, resulting in zero net change to his stockholding. This is a routine stock-compensation exercise: he converted equity awards into shares and immediately liquidated them at a gain. His 29 open-market sales over three years against zero open-market purchases reveal a consistent pattern of exercising vested compensation and selling—not a pattern of convictions about the stock's direction. His prior four sales at this company show mixed timing, with two followed by stock declines and two followed by gains. The company's fundamentals show losses and significant recent revenue decline, making this exercise-and-sell a straightforward liquidity event rather than a statement about company prospects. Given the repetitive nature of his trades and the lack of any accumulated position, this filing is routine insider compensation realization.

EVP/CCO Callos sells 26,000 CYTK shares (28.4% of holdings) for $1.6M; second major sale in 3 months amid unprofitable operations.

Andrew Callos, EVP and Chief Commercial Officer, executed 2 separate sales on 2026-03-05, selling 26,000 shares (26.0K shares) for $1,608,730.00 at a blended average price of $61.87, reducing his position from 91,440 shares to 65,440 shares. This represents a 28.4% reduction in holdings within 3 months following a prior sell on 2025-12-05. Cytokinetics is unprofitable with net income of $-306,178,000.00 over its most recent full fiscal year, though revenue grew 376.6% year-over-year; the current stock price of $62.19 is 11.3% below the 52-week high and has declined 3.9% over the past 30 days. Across Callos' cross-ticker open-market trade history, his 2 prior sells showed an average 90-day return of -14.9% with a 100.00% well-timed rate, and his 2 prior CYTK-specific sales both posted negative 90-day returns (-6.4% and -11.4%), indicating a pattern of selling ahead of subsequent declines at this ticker. The repetition of substantial sales within a short window warrants investor scrutiny of the underlying business outlook, particularly given the company's current unprofitability despite strong revenue growth.

CCO Andrew Callos sells 52.5K CYTK shares (-50.9% of holdings) at $65.95; prior sell at this ticker showed -24.1% 90d return

Callos sold 52,486 shares (50.9% of his holdings) at $65.95, a price near the 52-week high of $68.15. His cross-ticker track record shows a 100.00% well-timed rate at the 90-day mark, with his one prior CYTK sale on 2025-03-13 delivering a -24.1% return over 90 days—a pattern consistent with selling before subsequent declines. This substantial reduction in position size coincides with CYTK trading at elevated levels: the stock is up 11.0% over 30 days and 23.9% over 90 days, moving within 3.6% of its 52-week high. The company remains unprofitable (net income of $-306.2M in the latest period), though revenue has grown 145.3% year-over-year. The combination of a senior executive liquidating half his stake near a 52-week high, paired with his historical pattern of well-timed exits, warrants investor attention as the stock approaches valuation peaks.

CCO Callos Andrew sold 26,771 shares of CYTK at $43.62 on 2025-03-13, reducing holdings by 41.5% to 37,663 shares.

Callos Andrew, Chief Commercial Officer, executed a material reduction of his CYTK holdings, divesting 26,771 shares (41.5% of pre-transaction position) for $1,167,751.02. The company is currently unprofitable with a $-160,545,000.00 net loss in its most recent fiscal year, though annual revenue growth reached +145.3% year-over-year. The sale occurred at $43.62 while the current stock price stands at $44.40, positioning the transaction near recent trading levels but well below the 52-week high of $75.05 (currently -40.8% from that peak). This substantial reduction in the CCO's direct holdings warrants attention given the company's unprofitable status and the scale of the divestiture relative to his prior ownership stake.